Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand.

The impact of China's national essential medicine system on improving rational drug use in primary health care facilities: an empirical study in four provinces. BMC Health Serv Res (2014) 0.92

A dog's breakfast: prescription drug coverage varies widely across Canada. Med Care (2001) 4.07

Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J (2006) 3.65

The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s. Health Econ (2005) 3.61

Increased thrombotic vascular events after change of statin. Lancet (1998) 3.34

Is PHARMAC's sole-supply tendering policy harming the health of New Zealanders? N Z Med J (2005) 2.96

The Common Drug Review: a NICE start for Canada? Health Policy (2005) 2.58

Fluvastatin: what is the evidence? N Z Med J (1997) 2.54

Achieving equity in the Australian healthcare system. Med J Aust (2003) 2.13

PHARMAC and the statin debacle. N Z Med J (2006) 2.07

Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998. CMAJ (2000) 1.93

How low can it go? Projecting ischaemic heart disease mortality in New Zealand to 2015. N Z Med J (2006) 1.74

Lipid-modifying drugs. N Z Med J (1998) 1.72

Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment. Can J Clin Pharmacol (2002) 1.71

Excess coronary mortality among Australian men and women living outside the capital city statistical divisions. Med J Aust (2000) 1.64

Risk factors for cardiovascular disease in Canada. Can J Cardiol (2003) 1.64

Reference pricing--is it in the public interest? N Z Med J (2000) 1.62

Dihydropyridines, felodipine, and PHARMAC. N Z Med J (2005) 1.58

Timeliness of review and approval of new drugs in Canada from 1999 through 2001: is progress being made? Clin Ther (2003) 1.52

Heart failure: how can we prevent the epidemic? Med J Aust (2003) 1.50

The sorry saga of the statins in New Zealand--pharmacopolitics versus patient care. N Z Med J (2003) 1.48

Long-acting inhaled bronchodilators for COPD--lack of logic continues. N Z Med J (2005) 1.42

PHARMAC and lack of funding for clopidogrel. N Z Med J (2005) 1.41

Issues in the approval of, access to, and post-marketing follow-up of new drugs in Canada: a personal viewpoint. Pharmacoepidemiol Drug Saf (2002) 1.41

PHARMAC and Ventolin in New Zealand. N Z Med J (2005) 1.41

Acute Coronary Syndrome patients in New Zealand receive less invasive management when admitted to hospitals without invasive facilities. N Z Med J (2004) 1.29

Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. CMAJ (2006) 1.28

Management of patients admitted with an Acute Coronary Syndrome in New Zealand: results of a comprehensive nationwide audit. N Z Med J (2004) 1.24

Canadian health expenditures: where do we really stand internationally? CMAJ (1999) 1.23

The impact of reference pricing on clinical lipid control. N Z Med J (1998) 1.20

Approval process and access to prescription drugs in Canada. Arthritis Rheum (2006) 1.15

"Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement. Can J Public Health (2002) 1.07

Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics (2002) 1.06

Cardiac rehabilitation services in New Zealand: access and utilisation. N Z Med J (2004) 1.06

Changes in cardiovascular deaths and hospitalization in Canada. Can J Cardiol (2006) 1.04

Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices. CMAJ (2006) 1.02

PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists. N Z Med J (2005) 0.97

Health expenditure trends in OECD countries, 1990-2001. Health Care Financ Rev (2003) 0.96

Declining rates of coronary heart disease in New Zealand and Australia, 1983-1993. Am J Epidemiol (1997) 0.96

Is the United States an outlier in health care and health outcomes? A preliminary analysis. Int J Health Care Finance Econ (2006) 0.90

Pharmacological treatment of congestive heart failure in Canada: a description of care in five provinces. Can J Cardiol (2005) 0.90

Reimbursement of pharmaceuticals in New Zealand: comments on PHARMAC's processes. N Z Med J (2000) 0.89

PHARMAC Mark 2: towards agreed solutions? N Z Med J (2000) 0.88

Heart health has an adverse future forecast in New Zealand: an alarm call to action across the continuum. N Z Med J (2006) 0.84

Response from PHARMAC: difficult choices. N Z Med J (2003) 0.84

Heart attacks and unstable angina (acute coronary syndromes) have doubled in New Zealand since 1989: how do we best manage the epidemic? N Z Med J (2005) 0.83

Mortality from cardiovascular disease is too high outside capital cities. Med J Aust (2000) 0.80

Quality and equity in cardiovascular health in New Zealand: the need for agreed achievable standards of care, cohesive planning, and action. N Z Med J (2004) 0.79

Data for evaluating drugs is often poor, say experts. BMJ (2005) 0.77

Health services at breaking point. ...don't panic? N Z Med J (2002) 0.77

PHARMAC responds on salbutamol. N Z Med J (2005) 0.76

Heart failure: ethnic disparities in morbidity and mortality in New Zealand. N Z Med J (2002) 0.76

Regional revascularization patterns after myocardial infarction in Ontario. Can J Cardiol (1995) 0.76

PHARMAC responds on long-acting inhalers for COPD. N Z Med J (2005) 0.76

Statins and PHARMAC. N Z Med J (1999) 0.76

Asthma in New Zealand--time to get control. N Z Med J (2003) 0.76

Need for an improved submission process for listing drugs for reimbursement in Canadian provinces. Can J Clin Pharmacol (2003) 0.76

Statins and Pharmac. N Z Med J (1998) 0.76

Fluvastatin. N Z Med J (1997) 0.76

PHARMAC's response on clopidogrel. N Z Med J (2006) 0.75